Palvella Therapeutics Total Liabilities and Share Holders Equity 2014-2024 | PVLA

Palvella Therapeutics total liabilities and share holders equity from 2014 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.

Palvella Therapeutics Total Liabilities and Share Holders Equity 2014-2024 | PVLA

Palvella Therapeutics total liabilities and share holders equity from 2014 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$139.4B
Gilead Sciences (GILD)$114.7B
Bristol Myers Squibb (BMY)$113.7B
Vertex Pharmaceuticals (VRTX)$102.8B
CSL (CSLLY)$85.4B
Regeneron Pharmaceuticals (REGN)$77.2B
GSK (GSK)$69.7B
Argenex SE (ARGX)$37.4B
Alnylam Pharmaceuticals (ALNY)$30.4B
BioNTech SE (BNTX)$27B
Biogen (BIIB)$21.9B
Illumina (ILMN)$21.2B
BeiGene (BGNE)$17.9B
Moderna (MRNA)$15.2B
Genmab (GMAB)$13.7B
Incyte (INCY)$13.2B
BioMarin Pharmaceutical (BMRN)$12.5B
Insmed (INSM)$12.3B
Sarepta Therapeutics (SRPT)$11.6B
Bio-Techne Corp (TECH)$11.5B
Exact Sciences (EXAS)$10.4B
Vaxcyte (PCVX)$10.2B
QIAGEN (QGEN)$10.2B
Swedish Orphan Biovitrum (BIOVF)$9.8B
Exelixis (EXEL)$9.6B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$8.9B
Roivant Sciences (ROIV)$8.3B
Ascendis Pharma (ASND)$8.3B
Repligen (RGEN)$8.1B